|
1
|
Desrosiers R, Friderici K and Rottman F:
Identification of methylated nucleosides in messenger RNA from
Novikoff hepatoma cells. Proc Natl Acad Sci USA. 71:3971–3975.
1974.
|
|
2
|
Perry RP, Kelley DE, Friderici K and
Rottman F: The methylated constituents of L cell messenger RNA:
Evidence for an unusual cluster at the 5′ terminus. Cell.
4:387–394. 1975.
|
|
3
|
Dominissini D, Moshitch-Moshkovitz S,
Schwartz S, Salmon-Divon M, Ungar L, Osenberg S, Cesarkas K,
Jacob-Hirsch J, Amariglio N, Kupiec M, et al: Topology of the human
and mouse m6A RNA methylomes revealed by m6A-seq. Nature.
485:201–206. 2012.
|
|
4
|
Meyer KD, Saletore Y, Zumbo P, Elemento O,
Mason CE and Jaffrey SR: Comprehensive analysis of mRNA methylation
reveals enrichment in 3′ UTRs and near stop codons. Cell.
149:1635–1646. 2012.
|
|
5
|
Pavlova NN and Thompson CB: The emerging
hallmarks of cancer metabolism. Cell Metab. 23:27–47. 2016.
|
|
6
|
Zhang B, Wu Q, Li B, Wang D, Wang L and
Zhou YL: m6A regulator-mediated methylation modification
patterns and tumor microenvironment infiltration characterization
in gastric cancer. Mol Cancer. 19:532020.
|
|
7
|
Shen C, Xuan B, Yan T, Ma Y, Xu P, Tian X,
Zhang X, Cao Y, Ma D, Zhu X, et al: m6A-dependent
glycolysis enhances colorectal cancer progression. Mol Cancer.
19:722020.
|
|
8
|
Liu Y, Liang G, Xu H, Dong W, Dong Z, Qiu
Z, Zhang Z, Li F, Huang Y, Li Y, et al: Tumors exploit FTO-mediated
regulation of glycolytic metabolism to evade immune surveillance.
Cell Metab. 33:1221–1233.e11. 2021.
|
|
9
|
Shen M, Li Y, Wang Y, Shao J, Zhang F, Yin
G, Chen A, Zhang Z and Zheng S: N6-methyladenosine
modification regulates ferroptosis through autophagy signaling
pathway in hepatic stellate cells. Redox Biol. 47:1021512021.
|
|
10
|
Uddin MB, Wang Z and Yang C: The
m6A RNA methylation regulates oncogenic signaling
pathways driving cell malignant transformation and carcinogenesis.
Mol Cancer. 20:612021.
|
|
11
|
Li Q, Ni Y, Zhang L, Jiang R, Xu J, Yang
H, Hu Y, Qiu J, Pu L, Tang J and Wang X: HIF-1α-induced expression
of m6A reader YTHDF1 drives hypoxia-induced autophagy and
malignancy of hepatocellular carcinoma by promoting ATG2A and ATG14
translation. Signal Transduct Target Ther. 6:762021.
|
|
12
|
Bokar JA, Rath-Shambaugh ME, Ludwiczak R,
Narayan P and Rottman F: Characterization and partial purification
of mRNA N6-adenosine methyltransferase from HeLa cell nuclei.
Internal mRNA methylation requires a multisubunit complex. J Biol
Chem. 269:17697–11704. 1994.
|
|
13
|
Lin S, Choe J, Du P, Triboulet R and
Gregory RI: The m(6)A methyltransferase METTL3 promotes translation
in human cancer cells. Mol Cell. 62:335–345. 2016.
|
|
14
|
Wang Q, Chen C, Ding Q, Zhao Y, Wang Z,
Chen J, Jiang Z, Zhang Y, Xu G, Zhang J, et al: METTL3-mediated
m6A modification of HDGF mRNA promotes gastric cancer
progression and has prognostic significance. Gut. 69:1193–1205.
2020.
|
|
15
|
Xia T, Wu X, Cao M, Zhang P, Shi G, Zhang
J, Lu Z, Wu P, Cai B, Miao Y and Jiang K: The RNA m6A
methyltransferase METTL3 promotes pancreatic cancer cell
proliferation and invasion. Pathol Res Pract. 215:1526662019.
|
|
16
|
Liu J, Yue Y, Han D, Wang X, Fu Y, Zhang
L, Jia G, Yu M, Lu Z, Deng X, et al: A METTL3-METTL14 complex
mediates mammalian nuclear RNA N6-adenosine methylation. Nat Chem
Biol. 10:93–95. 2014.
|
|
17
|
Coker H, Wei G, Moindrot B, Mohammed S,
Nesterova T and Brockdorff N: The role of the Xist 5′ m6A region
and RBM15 in X chromosome inactivation. Wellcome Open Res.
5:312020.
|
|
18
|
Lan T, Li H, Zhang D, Xu L, Liu H, Hao X,
Yan X, Liao H, Chen X, Xie K, et al: KIAA1429 contributes to liver
cancer progression through N6-methyladenosine-dependent
post-transcriptional modification of GATA3. Mol Cancer.
18:1862019.
|
|
19
|
Ping XL, Sun BF, Wang L, Xiao W, Yang X,
Wang WJ, Adhikari S, Shi Y, Lv Y, Chen YS, et al: Mammalian WTAP is
a regulatory subunit of the RNA N6-methyladenosine
methyltransferase. Cell Res. 24:177–189. 2014.
|
|
20
|
Bawankar P, Lence T, Paolantoni C,
Haussmann IU, Kazlauskiene M, Jacob D, Heidelberger JB, Richter FM,
Nallasivan MP, Morin V, et al: Hakai is required for stabilization
of core components of the m6A mRNA methylation
machinery. Nat Commun. 12:37782021.
|
|
21
|
Wen J, Lv R, Ma H, Shen H, He C, Wang J,
Jiao F, Liu H, Yang P, Tan L, et al: Zc3h13 regulates nuclear RNA
m6A methylation and mouse embryonic stem cell
self-renewal. Mol Cell. 69:1028–1038.e6. 2018.
|
|
22
|
Pendleton KE, Chen B, Liu K, Hunter OV,
Xie Y, Tu BP and Conrad NK: The U6 snRNA m6A
methyltransferase METTL16 regulates SAM synthetase intron
retention. Cell. 169:824–835.e14. 2017.
|
|
23
|
Ruszkowska A: METTL16,
methyltransferase-like protein 16: Current insights into structure
and function. Int J Mol Sci. 22:21762021.
|
|
24
|
Jia G, Fu Y, Zhao X, Dai Q, Zheng G, Yang
Y, Yi C, Lindahl T, Pan T, Yang YG and He C: N6-methyladenosine in
nuclear RNA is a major substrate of the obesity-associated FTO. Nat
Chem Biol. 7:885–887. 2011.
|
|
25
|
Zheng G, Dahl JA, Niu Y, Fedorcsak P,
Huang CM, Li CJ, Vågbø CB, Shi Y, Wang WL, Song SH, et al: ALKBH5
is a mammalian RNA demethylase that impacts RNA metabolism and
mouse fertility. Mol Cell. 49:18–29. 2013.
|
|
26
|
Zhao X, Yang Y, Sun BF, Shi Y, Yang X,
Xiao W, Hao YJ, Ping XL, Chen YS, Wang WJ, et al: FTO-dependent
demethylation of N6-methyladenosine regulates mRNA splicing and is
required for adipogenesis. Cell Res. 24:1403–1419. 2014.
|
|
27
|
Chen Z, Qi M, Shen B, Luo G, Wu Y, Li J,
Lu Z, Zheng Z, Dai Q and Wang H: Transfer RNA demethylase ALKBH3
promotes cancer progression via induction of tRNA-derived small
RNAs. Nucleic Acids Res. 47:2533–2545. 2019.
|
|
28
|
Huang H, Weng H, Sun W, Qin X, Shi H, Wu
H, Zhao BS, Mesquita A, Liu C, Yuan CL, et al: Recognition of RNA
N6-methyladenosine by IGF2BP proteins enhances mRNA
stability and translation. Nat Cell Biol. 20:285–295. 2018.
|
|
29
|
Alarcón CR, Goodarzi H, Lee H, Liu X,
Tavazoie S and Tavazoie SF: HNRNPA2B1 is a mediator of
m(6)A-dependent nuclear RNA processing events. Cell. 162:1299–1308.
2015.
|
|
30
|
Cheng M, Sheng L, Gao Q, Xiong Q, Zhang H,
Wu M, Liang Y, Zhu F, Zhang Y, Zhang X, et al: The m6A
methyltransferase METTL3 promotes bladder cancer progression via
AFF4/NF-κB/MYC signaling network. Oncogene. 38:3667–3680. 2019.
|
|
31
|
Han J, Wang JZ, Yang X, Yu H, Zhou R, Lu
HC, Yuan WB, Lu JC, Zhou ZJ, Lu Q, et al: METTL3 promote tumor
proliferation of bladder cancer by accelerating pri-miR221/222
maturation in m6A-dependent manner. Mol Cancer. 18:1102019.
|
|
32
|
Li T, Hu PS, Zuo Z, Lin JF, Li X, Wu QN,
Chen ZH, Zeng ZL, Wang F, Zheng J, et al: METTL3 facilitates tumor
progression via an m6A-IGF2BP2-dependent mechanism in
colorectal carcinoma. Mol Cancer. 18:1122019.
|
|
33
|
Yue B, Song C, Yang L, Cui R, Cheng X,
Zhang Z and Zhao G: METTL3-mediated N6-methyladenosine modification
is critical for epithelial-mesenchymal transition and metastasis of
gastric cancer. Mol Cancer. 18:1422019.
|
|
34
|
Wang M, Liu J, Zhao Y, He R, Xu X, Guo X,
Li X, Xu S, Miao J, Guo J, et al: Upregulation of METTL14 mediates
the elevation of PERP mRNA N6 adenosine methylation
promoting the growth and metastasis of pancreatic cancer. Mol
Cancer. 19:1302020.
|
|
35
|
Yang X, Zhang S, He C, Xue P, Zhang L, He
Z, Zang L, Feng B, Sun J and Zheng M: METTL14 suppresses
proliferation and metastasis of colorectal cancer by
down-regulating oncogenic long non-coding RNA XIST. Mol Cancer.
19:462020.
|
|
36
|
Chen X, Xu M, Xu X, Zeng K, Liu X, Pan B,
Li C, Sun L, Qin J, Xu T, et al: METTL14-mediated
N6-methyladenosine modification of SOX4 mRNA inhibits tumor
metastasis in colorectal cancer. Mol Cancer. 19:1062020.
|
|
37
|
Liu X, Xiao M, Zhang L, Li L, Zhu G, Shen
E, Lv M, Lu X and Sun Z: The m6A methyltransferase METTL14 inhibits
the proliferation, migration, and invasion of gastric cancer by
regulating the PI3K/AKT/mTOR signaling pathway. J Clin Lab Anal.
35:e236552021.
|
|
38
|
Yao Q, He L, Gao X, Tang N, Lin L, Yu X
and Wang D: The m6A methyltransferase METTL14-mediated
N6-methyladenosine modification of PTEN mRNA inhibits tumor growth
and metastasis in stomach adenocarcinoma. Front Oncol.
11:6997492021.
|
|
39
|
Gong PJ, Shao YC, Yang Y, Song WJ, He X,
Zeng YF, Huang SR, Wei L and Zhang JW: Analysis of
N6-methyladenosine methyltransferase reveals METTL14 and ZC3H13 as
tumor suppressor genes in breast cancer. Front Oncol.
10:5789632020.
|
|
40
|
Chen Y, Peng C, Chen J, Chen D, Yang B, He
B, Hu W, Zhang Y, Liu H, Dai L, et al: WTAP facilitates progression
of hepatocellular carcinoma via m6A-HuR-dependent epigenetic
silencing of ETS1. Mol Cancer. 18:1272019.
|
|
41
|
Zhao W and Xie Y: KIAA1429 promotes the
progression of lung adenocarcinoma by regulating the m6A level of
MUC3A. Pathol Res Pract. 217:1532842021.
|
|
42
|
Su R, Dong L, Li Y, Gao M, He PC, Liu W,
Wei J, Zhao Z, Gao L, Han L, et al: METTL16 exerts an
m6A-independent function to facilitate translation and
tumorigenesis. Nat Cell Biol. 24:205–216. 2022.
|
|
43
|
Xu Y, Ye S, Zhang N, Zheng S, Liu H, Zhou
K, Wang L, Cao Y, Sun P and Wang T: The FTO/miR-181b-3p/ARL5B
signaling pathway regulates cell migration and invasion in breast
cancer. Cancer Commun (Lond). 40:484–500. 2020.
|
|
44
|
Tao L, Mu X, Chen H, Jin D, Zhang R, Zhao
Y, Fan J, Cao M and Zhou Z: FTO modifies the m6A level of MALAT and
promotes bladder cancer progression. Clin Transl Med.
11:e3102021.
|
|
45
|
Zhang L, Wan Y, Zhang Z, Jiang Y, Lang J,
Cheng W and Zhu L: FTO demethylates m6A modifications in HOXB13
mRNA and promotes endometrial cancer metastasis by activating the
WNT signalling pathway. RNA Biol. 18:1265–1278. 2021.
|
|
46
|
Shen C, Sheng Y, Zhu AC, Robinson S, Jiang
X, Dong L, Chen H, Su R, Yin Z, Li W, et al: RNA demethylase ALKBH5
selectively promotes tumorigenesis and cancer stem cell
self-renewal in acute myeloid leukemia. Cell Stem Cell.
27:64–80.e9. 2020.
|
|
47
|
Nie S, Zhang L, Liu J, Wan Y, Jiang Y,
Yang J, Sun R, Ma X, Sun G, Meng H, et al: ALKBH5-HOXA10
loop-mediated JAK2 m6A demethylation and cisplatin resistance in
epithelial ovarian cancer. J Exp Clin Cancer Res. 40:2842021.
|
|
48
|
Zhu H, Gan X, Jiang X, Diao S, Wu H and Hu
J: ALKBH5 inhibited autophagy of epithelial ovarian cancer through
miR-7 and BCL-2. J Exp Clin Cancer Res. 38:1632019.
|
|
49
|
Zhang C, Samanta D, Lu H, Bullen JW, Zhang
H, Chen I, He X and Semenza GL: Hypoxia induces the breast cancer
stem cell phenotype by HIF-dependent and ALKBH5-mediated
m6A-demethylation of NANOG mRNA. Proc Natl Acad Sci USA.
113:E2047–E2056. 2016.
|
|
50
|
Zhang J, Guo S, Piao HY, Wang Y, Wu Y,
Meng XY, Yang D, Zheng ZC and Zhao Y: ALKBH5 promotes invasion and
metastasis of gastric cancer by decreasing methylation of the
lncRNA NEAT1. J Physiol Biochem. 75:379–389. 2019.
|
|
51
|
Tang B, Yang Y, Kang M, Wang Y, Wang Y, Bi
Y, He S and Shimamoto F: m6A demethylase ALKBH5 inhibits
pancreatic cancer tumorigenesis by decreasing WIF-1 RNA methylation
and mediating Wnt signaling. Mol Cancer. 19:32020.
|
|
52
|
Guo X, Li K, Jiang W, Hu Y, Xiao W, Huang
Y, Feng Y, Pan Q and Wan R: RNA demethylase ALKBH5 prevents
pancreatic cancer progression by posttranscriptional activation of
PER1 in an m6A-YTHDF2-dependent manner. Mol Cancer. 19:912020.
|
|
53
|
Liu T, Wei Q, Jin J, Luo Q, Liu Y, Yang Y,
Cheng C, Li L, Pi J, Si Y, et al: The m6A reader YTHDF1 promotes
ovarian cancer progression via augmenting EIF3C translation.
Nucleic Acids Res. 48:3816–3831. 2020.
|
|
54
|
Dixit D, Prager BC, Gimple RC, Poh HX,
Wang Y, Wu Q, Qiu Z, Kidwell RL, Kim LJY, Xie Q, et al: The RNA m6A
reader YTHDF2 maintains oncogene expression and is a targetable
dependency in glioblastoma stem cells. Cancer Discov. 11:480–499.
2021.
|
|
55
|
Fang R, Chen X, Zhang S, Shi H, Ye Y, Shi
H, Zou Z, Li P, Guo Q, Ma L, et al: EGFR/SRC/ERK-stabilized YTHDF2
promotes cholesterol dysregulation and invasive growth of
glioblastoma. Nat Commun. 12:1772021.
|
|
56
|
Li J, Xie H, Ying Y, Chen H, Yan H, He L,
Xu M, Xu X, Liang Z, Liu B, et al: YTHDF2 mediates the mRNA
degradation of the tumor suppressors to induce AKT phosphorylation
in N6-methyladenosine-dependent way in prostate cancer. Mol Cancer.
19:1522020.
|
|
57
|
Zhang C, Huang S, Zhuang H, Ruan S, Zhou
Z, Huang K, Ji F, Ma Z, Hou B and He X: YTHDF2 promotes the liver
cancer stem cell phenotype and cancer metastasis by regulating OCT4
expression via m6A RNA methylation. Oncogene. 39:4507–4518.
2020.
|
|
58
|
Zhong L, Liao D, Zhang M, Zeng C, Li X,
Zhang R, Ma H and Kang T: YTHDF2 suppresses cell proliferation and
growth via destabilizing the EGFR mRNA in hepatocellular carcinoma.
Cancer Lett. 442:252–261. 2019.
|
|
59
|
Chang G, Shi L, Ye Y, Shi H, Zeng L,
Tiwary S, Huse JT, Huo L, Ma L, Ma Y, et al: YTHDF3 Induces the
translation of m6A-enriched gene transcripts to promote
breast cancer brain metastasis. Cancer Cell. 38:857–871.e7.
2020.
|
|
60
|
Ni W, Yao S, Zhou Y, Liu Y, Huang P, Zhou
A, Liu J, Che L and Li J: Long noncoding RNA GAS5 inhibits
progression of colorectal cancer by interacting with and triggering
YAP phosphorylation and degradation and is negatively regulated by
the m6A reader YTHDF3. Mol Cancer. 18:1432019.
|
|
61
|
Jiang X, Liu B, Nie Z, Duan L, Xiong Q,
Jin Z, Yang C and Chen Y: The role of m6A modification in the
biological functions and diseases. Signal Transduct Target Ther.
6:742021.
|
|
62
|
Li S, Qi Y, Yu J, Hao Y, He B, Zhang M,
Dai Z, Jiang T, Li S, Huang F, et al: Nuclear Aurora kinase A
switches m6A reader YTHDC1 to enhance an oncogenic RNA
splicing of tumor suppressor RBM4. Signal Transduct Target Ther.
7:972022.
|
|
63
|
Li Y, Zheng JN, Wang EH, Gong CJ, Lan KF
and Ding X: The m6A reader protein YTHDC2 is a potential biomarker
and associated with immune infiltration in head and neck squamous
cell carcinoma. PeerJ. 8:e103852020.
|
|
64
|
Sun S, Han Q, Liang M, Zhang Q, Zhang J
and Cao J: Downregulation of m6 A reader YTHDC2 promotes
tumor progression and predicts poor prognosis in non-small cell
lung cancer. Thorac Cancer. 11:3269–3279. 2020.
|
|
65
|
Wang J, Tan L, Jia B, Yu X, Yao R, OUYang
N, Yu X, Cao X, Tong J, Chen T, et al: Downregulation of
m6A reader YTHDC2 promotes the proliferation and
migration of malignant lung cells via CYLD/NF-κB pathway. Int J
Biol Sci. 17:2633–2651. 2021.
|
|
66
|
Müller S, Bley N, Glaß M, Busch B,
Rousseau V, Misiak D, Fuchs T, Lederer M and Hüttelmaier S: IGF2BP1
enhances an aggressive tumor cell phenotype by impairing
miRNA-directed downregulation of oncogenic factors. Nucleic Acids
Res. 46:6285–6303. 2018.
|
|
67
|
Müller S, Glaß M, Singh AK, Haase J, Bley
N, Fuchs T, Lederer M, Dahl A, Huang H, Chen J, et al: IGF2BP1
promotes SRF-dependent transcription in cancer in a m6A- and
miRNA-dependent manner. Nucleic Acids Res. 47:375–390. 2019.
|
|
68
|
Zhang L, Wan Y, Zhang Z, Jiang Y, Gu Z, Ma
X, Nie S, Yang J, Lang J, Cheng W and Zhu L: IGF2BP1 overexpression
stabilizes PEG10 mRNA in an m6A-dependent manner and promotes
endometrial cancer progression. Theranostics. 11:1100–1114.
2021.
|
|
69
|
Hu X, Peng WX, Zhou H, Jiang J, Zhou X,
Huang D, Mo YY and Yang L: IGF2BP2 regulates DANCR by serving as an
N6-methyladenosine reader. Cell Death Differ. 27:1782–1794.
2020.
|
|
70
|
Cui J, Tian J, Wang W, He T, Li X, Gu C,
Wang L, Wu J and Shang A: IGF2BP2 promotes the progression of
colorectal cancer through a YAP-dependent mechanism. Cancer Sci.
112:4087–4099. 2021.
|
|
71
|
Yu D, Pan M, Li Y, Lu T, Wang Z, Liu C and
Hu G: RNA N6-methyladenosine reader IGF2BP2 promotes lymphatic
metastasis and epithelial-mesenchymal transition of head and neck
squamous carcinoma cells via stabilizing slug mRNA in an
m6A-dependent manner. J Exp Clin Cancer Res. 41:62022.
|
|
72
|
Yang Z, Wang T, Wu D, Min Z, Tan J and Yu
B: RNA N6-methyladenosine reader IGF2BP3 regulates cell cycle and
angiogenesis in colon cancer. J Exp Clin Cancer Res.
39:2032020.
|
|
73
|
Huang W, Li Y, Zhang C, Zha H, Zhou X, Fu
B, Guo J and Wang G: IGF2BP3 facilitates cell proliferation and
tumorigenesis via modulation of JAK/STAT signalling pathway in
human bladder cancer. J Cell Mol Med. 24:13949–13960. 2020.
|
|
74
|
Lin H, Wang Y, Wang P, Long F and Wang T:
Mutual regulation between N6-methyladenosine (m6A) modification and
circular RNAs in cancer: Impacts on therapeutic resistance. Mol
Cancer. 21:1482022.
|
|
75
|
Xie F, Huang C, Liu F, Zhang H, Xiao X,
Sun J, Zhang X and Jiang G: CircPTPRA blocks the recognition of RNA
N6-methyladenosine through interacting with IGF2BP1 to suppress
bladder cancer progression. Mol Cancer. 20:682021.
|
|
76
|
Li B, Zhu L, Lu C, Wang C, Wang H, Jin H,
Ma X, Cheng Z, Yu C, Wang S, et al: circNDUFB2 inhibits non-small
cell lung cancer progression via destabilizing IGF2BPs and
activating anti-tumor immunity. Nat Commun. 12:2952021.
|
|
77
|
Hay N: Reprogramming glucose metabolism in
cancer: Can it be exploited for cancer therapy? Nat Rev Cancer.
16:635–649. 2016.
|
|
78
|
Tan YT, Lin JF, Li T, Li JJ, Xu RH and Ju
HQ: LncRNA-mediated posttranslational modifications and
reprogramming of energy metabolism in cancer. Cancer Commun (Lond).
41:109–120. 2021.
|
|
79
|
Vaupel P, Schmidberger H and Mayer A: The
Warburg effect: Essential part of metabolic reprogramming and
central contributor to cancer progression. Int J Radiat Biol.
95:912–919. 2019.
|
|
80
|
Li Z, Peng Y, Li J, Chen Z, Chen F, Tu J,
Lin S and Wang H: N6-methyladenosine regulates
glycolysis of cancer cells through PDK4. Nat Commun.
11:25782020.
|
|
81
|
Chen H, Gao S, Liu W, Wong CC, Wu J, Wu J,
Liu D, Gou H, Kang W, Zhai J, et al: RNA
N6-methyladenosine methyltransferase METTL3 facilitates
colorectal cancer by activating the m6A-GLUT1-mTORC1 axis and is a
therapeutic target. Gastroenterology. 160:1284–1300. e162021.
|
|
82
|
Wang Q, Guo X, Li L, Gao Z, Su X, Ji M and
Liu J: N6-methyladenosine METTL3 promotes cervical
cancer tumorigenesis and Warburg effect through YTHDF1/HK2
modification. Cell Death Dis. 11:9112020.
|
|
83
|
Zhang C, Chen L, Liu Y, Huang J, Liu A, Xu
Y, Shen Y, He H and Xu D: Downregulated METTL14 accumulates BPTF
that reinforces super-enhancers and distal lung metastasis via
glycolytic reprogramming in renal cell carcinoma. Theranostics.
11:3676–3693. 2021.
|
|
84
|
Ou B, Liu Y, Yang X, Xu X, Yan Y and Zhang
J: C5aR1-positive neutrophils promote breast cancer glycolysis
through WTAP-dependent m6A methylation of ENO1. Cell Death Dis.
12:7372021.
|
|
85
|
Yu H, Zhao K, Zeng H, Li Z, Chen K, Zhang
Z, Li E and Wu Z: N6-methyladenosine (m6A)
methyltransferase WTAP accelerates the Warburg effect of gastric
cancer through regulating HK2 stability. Biomed Pharmacother.
133:1110752021.
|
|
86
|
Huang J, Sun W, Wang Z, Lv C, Zhang T,
Zhang D, Dong W, Shao L, He L, Ji X, et al: FTO suppresses
glycolysis and growth of papillary thyroid cancer via decreasing
stability of APOE mRNA in an N6-methyladenosine-dependent manner. J
Exp Clin Cancer Res. 41:422022.
|
|
87
|
Yu H, Yang X, Tang J, Si S, Zhou Z, Lu J,
Han J, Yuan B, Wu Q, Lu Q and Yang H: ALKBH5 inhibited cell
proliferation and sensitized bladder cancer cells to cisplatin by
m6A-CK2α-mediated glycolysis. Mol Ther Nucleic Acids. 23:27–41.
2020.
|
|
88
|
Liu H, Lyu H, Jiang G, Chen D, Ruan S, Liu
S, Zhou L, Yang M, Zeng S, He Z, et al: ALKBH5-mediated m6A
demethylation of GLUT4 mRNA promotes glycolysis and resistance to
HER2-targeted therapy in breast cancer. Cancer Res. 82:3974–3986.
2022.
|
|
89
|
Yao X, Li W, Li L, Li M, Zhao Y, Fang D,
Zeng X and Luo Z: YTHDF1 upregulation mediates hypoxia-dependent
breast cancer growth and metastasis through regulating PKM2 to
affect glycolysis. Cell Death Dis. 13:2582022.
|
|
90
|
Carracedo A, Cantley LC and Pandolfi PP:
Cancer metabolism: Fatty acid oxidation in the limelight. Nat Rev
Cancer. 13:227–232. 2013.
|
|
91
|
Currie E, Schulze A, Zechner R, Walther TC
and Farese RV Jr: Cellular fatty acid metabolism and cancer. Cell
Metab. 18:153–161. 2013.
|
|
92
|
Li Z and Zhang H: Reprogramming of
glucose, fatty acid and amino acid metabolism for cancer
progression. Cell Mol Life Sci. 73:377–392. 2016.
|
|
93
|
Butler LM, Perone Y, Dehairs J, Lupien LE,
de Laat V, Talebi A, Loda M, Kinlaw WB and Swinnen JV: Lipids and
cancer: Emerging roles in pathogenesis, diagnosis and therapeutic
intervention. Adv Drug Deliv Rev. 159:245–293. 2020.
|
|
94
|
Zuo X, Chen Z, Gao W, Zhang Y, Wang J,
Wang J, Cao M, Cai J, Wu J and Wang X: M6A-mediated upregulation of
LINC00958 increases lipogenesis and acts as a nanotherapeutic
target in hepatocellular carcinoma. J Hematol Oncol. 13:52020.
|
|
95
|
Yang Z, Yu GL, Zhu X, Peng TH and Lv YC:
Critical roles of FTO-mediated mRNA m6A demethylation in regulating
adipogenesis and lipid metabolism: Implications in lipid metabolic
disorders. Genes Dis. 9:51–61. 2021.
|
|
96
|
Sun D, Zhao T, Zhang Q, Wu M and Zhang Z:
Fat mass and obesity-associated protein regulates lipogenesis via
m6 A modification in fatty acid synthase mRNA. Cell Biol
Int. 45:334–344. 2021.
|
|
97
|
Duan X, Yang L, Wang L, Liu Q, Zhang K,
Liu S, Liu C, Gao Q, Li L, Qin G and Zhang Y: m6A demethylase FTO
promotes tumor progression via regulation of lipid metabolism in
esophageal cancer. Cell Biosci. 12:602022.
|
|
98
|
Altman BJ, Stine ZE and Dang CV: From
Krebs to clinic: Glutamine metabolism to cancer therapy. Nat Rev
Cancer. 16:619–634. 2016.
|
|
99
|
Wang Y, Bai C, Ruan Y, Liu M, Chu Q, Qiu
L, Yang C and Li B: Coordinative metabolism of glutamine carbon and
nitrogen in proliferating cancer cells under hypoxia. Nat Commun.
10:2012019.
|
|
100
|
Han S, Zhu L, Zhu Y, Meng Y, Li J, Song P,
Yousafzai NA, Feng L, Chen M, Wang Y, et al: Targeting
ATF4-dependent pro-survival autophagy to synergize glutaminolysis
inhibition. Theranostics. 11:8464–8479. 2021.
|
|
101
|
Okazaki A, Gameiro PA, Christodoulou D,
Laviollette L, Schneider M, Chaves F, Stemmer-Rachamimov A,
Yazinski SA, Lee R, Stephanopoulos G, et al: Glutaminase and
poly(ADP-ribose) polymerase inhibitors suppress pyrimidine
synthesis and VHL-deficient renal cancers. J Clin Invest.
127:1631–1645. 2017.
|
|
102
|
Xiao Y, Thakkar KN, Zhao H, Broughton J,
Li Y, Seoane JA, Diep AN, Metzner TJ, von Eyben R, Dill DL, et al:
The m6A RNA demethylase FTO is a HIF-independent
synthetic lethal partner with the VHL tumor suppressor. Proc Natl
Acad Sci USA. 117:21441–21449. 2020.
|
|
103
|
Chen P, Liu XQ, Lin X, Gao LY, Zhang S and
Huang X: Targeting YTHDF1 effectively re-sensitizes
cisplatin-resistant colon cancer cells by modulating GLS-mediated
glutamine metabolism. Mol Ther Oncolytics. 20:228–239. 2021.
|
|
104
|
Ma L, Chen T, Zhang X, Miao Y, Tian X, Yu
K, Xu X, Niu Y, Guo S, Zhang C, et al: The m6A reader
YTHDC2 inhibits lung adenocarcinoma tumorigenesis by suppressing
SLC7A11-dependent antioxidant function. Redox Biol.
38:1018012021.
|
|
105
|
Koppula P, Zhuang L and Gan B: Cystine
transporter SLC7A11/xCT in cancer: Ferroptosis, nutrient
dependency, and cancer therapy. Protein Cell. 12:599–620. 2021.
|
|
106
|
Hu Z, Yin Y, Jiang J, Yan C, Wang Y, Wang
D and Li L: Exosomal miR-142-3p secreted by hepatitis B virus
(HBV)-hepatocellular carcinoma (HCC) cells promotes ferroptosis of
M1-type macrophages through SLC3A2 and the mechanism of HCC
progression. J Gastrointest Oncol. 13:754–767. 2022.
|
|
107
|
Wang X, Chen Y, Wang X, Tian H, Wang Y,
Jin J, Shan Z, Liu Y, Cai Z, Tong X, et al: Stem cell factor SOX2
confers ferroptosis resistance in lung cancer via upregulation of
SLC7A11. Cancer Res. 81:5217–5229. 2021.
|
|
108
|
Wang W, Green M, Choi JE, Gijón M, Kennedy
PD, Johnson JK, Liao P, Lang X, Kryczek I, Sell A, et al:
CD8+ T cells regulate tumour ferroptosis during cancer
immunotherapy. Nature. 569:270–274. 2019.
|
|
109
|
Xu Y, Lv D, Yan C, Su H, Zhang X, Shi Y
and Ying K: METTL3 promotes lung adenocarcinoma tumor growth and
inhibits ferroptosis by stabilizing SLC7A11 m6A modification.
Cancer Cell Int. 22:112022.
|
|
110
|
Liu L, He J, Sun G, Huang N, Bian Z, Xu C,
Zhang Y, Cui Z, Xu W, Sun F, et al: The N6-methyladenosine
modification enhances ferroptosis resistance through inhibiting
SLC7A11 mRNA deadenylation in hepatoblastoma. Clin Transl Med.
12:e7782022.
|
|
111
|
Fan Z, Yang G, Zhang W, Liu Q, Liu G, Liu
P, Xu L, Wang J, Yan Z, Han H, et al: Hypoxia blocks ferroptosis of
hepato-cellular carcinoma via suppression of METTL14 triggered
YTHDF2-dependent silencing of SLC7A11. J Cell Mol Med.
25:10197–10212. 2021.
|
|
112
|
Ji FH, Fu XH, Li GQ, He Q and Qiu XG: FTO
prevents thyroid cancer progression by SLC7A11 m6A methylation in a
ferroptosis-dependent manner. Front Endocrinol (Lausanne).
13:8577652022.
|
|
113
|
Li W, Huang G, Wei J, Cao H and Jiang G:
ALKBH5 inhibits thyroid cancer progression by promoting ferroptosis
through TIAM1-Nrf2/HO-1 axis. Mol Cell Biochem. 478:729–741.
2023.
|
|
114
|
Ye J, Chen X, Jiang X, Dong Z, Hu S and
Xiao M: RNA demethylase ALKBH5 regulates hypopharyngeal squamous
cell carcinoma ferroptosis by posttranscriptionally activating
NFE2L2/NRF2 in an m6 A-IGF2BP2-dependent manner. J Clin
Lab Anal. 36:e245142022.
|
|
115
|
Yang H, Hu Y, Weng M, Liu X, Wan P, Hu Y,
Ma M, Zhang Y, Xia H and Lv K: Hypoxia inducible lncRNA-CBSLR
modulates ferroptosis through m6A-YTHDF2-dependent modulation of
CBS in gastric cancer. J Adv Res. 37:91–106. 2021.
|
|
116
|
Ma L, Zhang X, Yu K, Xu X, Chen T, Shi Y,
Wang Y, Qiu S, Guo S, Cui J, et al: Targeting SLC3A2 subunit of
system XC-is essential for m6A reader YTHDC2
to be an endogenous ferroptosis inducer in lung adenocarcinoma.
Free Radic Biol Med. 168:25–43. 2021.
|
|
117
|
Han Y, Liu D and Li L: PD-1/PD-L1 pathway:
Current researches in cancer. Am J Cancer Res. 10:727–742.
2020.
|
|
118
|
Xu-Monette ZY, Zhou J and Young KH: PD-1
expression and clinical PD-1 blockade in B-cell lymphomas. Blood.
131:68–83. 2018.
|
|
119
|
Yi M, Zheng X, Niu M, Zhu S, Ge H and Wu
K: Combination strategies with PD-1/PD-L1 blockade: Current
advances and future directions. Mol Cancer. 21:282022.
|
|
120
|
Buchmann K: Evolution of innate immunity:
Clues from Invertebrates via fish to mammals. Front Immunol.
5:4592014.
|
|
121
|
Gajewski TF, Schreiber H and Fu YX: Innate
and adaptive immune cells in the tumor microenvironment. Nat
Immunol. 14:1014–1022. 2013.
|
|
122
|
Yin H, Zhang X, Yang P, Zhang X, Peng Y,
Li D, Yu Y, Wu Y, Wang Y, Zhang J, et al: RNA m6A methylation
orchestrates cancer growth and metastasis via macrophage
reprogramming. Nat Commun. 12:13942021.
|
|
123
|
Li HB, Tong J, Zhu S, Batista PJ, Duffy
EE, Zhao J, Bailis W, Cao G, Kroehling L, Chen Y, et al:
m6A mRNA methylation controls T cell homeostasis by
targeting the IL-7/STAT5/SOCS pathways. Nature. 548:338–342.
2017.
|
|
124
|
Wan W, Ao X, Chen Q, Yu Y, Ao L, Xing W,
Guo W, Wu X, Pu C, Hu X, et al: METTL3/IGF2BP3 axis inhibits tumor
immune surveillance by upregulating N6-methyladenosine
modification of PD-L1 mRNA in breast cancer. Mol Cancer.
21:602022.
|
|
125
|
Ni Z, Sun P, Zheng J, Wu M, Yang C, Cheng
M, Yin M, Cui C, Wang G, Yuan L, et al: JNK signaling promotes
bladder cancer immune escape by regulating METTL3-mediated m6A
modification of PD-L1 mRNA. Cancer Res. 82:1789–1802. 2022.
|
|
126
|
Zheng H, Zheng WJ, Wang ZG, Tao YP, Huang
ZP, Yang L, Ouyang L, Duan ZQ, Zhang YN, Chen BN, et al: Decreased
expression of programmed death ligand-L1 by seven in absentia
homolog 2 in cholangiocarcinoma enhances T-cell-mediated antitumor
activity. Front Immunol. 13:8451932022.
|
|
127
|
Yang S, Wei J, Cui YH, Park G, Shah P,
Deng Y, Aplin AE, Lu Z, Hwang S, He C and He YY: m6A
mRNA demethylase FTO regulates melanoma tumorigenicity and response
to anti-PD-1 blockade. Nat Commun. 10:27822019.
|
|
128
|
Tsuruta N, Tsuchihashi K, Ohmura H,
Yamaguchi K, Ito M, Ariyama H, Kusaba H, Akashi K and Baba E: RNA
N6-methyladenosine demethylase FTO regulates PD-L1 expression in
colon cancer cells. Biochem Biophys Res Commun. 530:235–239.
2020.
|
|
129
|
Qiu X, Yang S, Wang S, Wu J, Zheng B, Wang
K, Shen S, Jeong S, Li Z, Zhu Y, et al: M6A demethylase
ALKBH5 regulates PD-L1 expression and tumor immunoenvironment in
intrahepatic cholangiocarcinoma. Cancer Res. 81:4778–4793.
2021.
|
|
130
|
You Y, Wen D, Zeng L, Lu J, Xiao X, Chen
Y, Song H and Liu Z: ALKBH5/MAP3K8 axis regulates PD-L1+ macrophage
infiltration and promotes hepatocellular carcinoma progression. Int
J Biol Sci. 18:5001–5018. 2022.
|
|
131
|
Hu J, Qiu D, Yu A, Hu J, Deng H, Li H, Yi
Z, Chen J and Zu X: YTHDF1 is a potential pan-cancer biomarker for
prognosis and immunotherapy. Front Oncol. 11:6072242021.
|
|
132
|
Han D, Liu J, Chen C, Dong L, Liu Y, Chang
R, Huang X, Liu Y, Wang J, Dougherty U, et al: Anti-tumour immunity
controlled through mRNA m6A methylation and YTHDF1 in
dendritic cells. Nature. 566:270–274. 2019.
|
|
133
|
Tsuchiya K, Yoshimura K, Inoue Y, Iwashita
Y, Yamada H, Kawase A, Watanabe T, Tanahashi M, Ogawa H, Funai K,
et al: YTHDF1 and YTHDF2 are associated with better patient
survival and an inflamed tumor-immune microenvironment in
non-small-cell lung cancer. Oncoimmunology. 10:19626562021.
|
|
134
|
Yang X and Liu J: Targeting PD-L1
(Programmed death-ligand 1) and inhibiting the expression of
IGF2BP2 (Insulin-like growth factor 2 mRNA-binding protein 2)
affect the proliferation and apoptosis of hypopharyngeal carcinoma
cells. Bioengineered. 12:7755–7764. 2021.
|
|
135
|
Yankova E, Blackaby W, Albertella M, Rak
J, De Braekeleer E, Tsagkogeorga G, Pilka ES, Aspris D, Leggate D,
Hendrick AG, et al: Small-molecule inhibition of METTL3 as a
strategy against myeloid leukaemia. Nature. 593:597–601. 2021.
|
|
136
|
Xu QC, Tien YC, Shi YH, Chen S, Zhu YQ,
Huang XT, Huang CS, Zhao W and Yin XY: METTL3 promotes intrahepatic
cholangiocarcinoma progression by regulating IFIT2 expression in an
m6A-YTHDF2-dependent manner. Oncogene. 41:1622–1633. 2022.
|
|
137
|
Huang Y, Su R, Sheng Y, Dong L, Dong Z, Xu
H, Ni T, Zhang ZS, Zhang T, Li C, et al: Small-molecule targeting
of oncogenic FTO demethylase in acute myeloid leukemia. Cancer
Cell. 35:677–691.e10. 2019.
|
|
138
|
Su R, Dong L, Li Y, Gao M, Han L,
Wunderlich M, Deng X, Li H, Huang Y, Gao L, et al: Targeting FTO
suppresses cancer stem cell maintenance and immune evasion. Cancer
Cell. 38:79–96.e11. 2020.
|
|
139
|
Su R, Dong L, Li C, Nachtergaele S,
Wunderlich M, Qing Y, Deng X, Wang Y, Weng X, Hu C, et al: R-2HG
exhibits anti-tumor activity by targeting
FTO/m6A/MYC/CEBPA signaling. Cell. 172:90–105.e23.
2018.
|
|
140
|
Fang Z, Mu B, Liu Y, Guo N, Xiong L, Guo
Y, Xia A, Zhang R, Zhang H, Yao R, et al: Discovery of a potent,
selective and cell active inhibitor of m6A demethylase
ALKBH5. Eur J Med Chem. 238:1144462022.
|
|
141
|
Takahashi H, Hase H, Yoshida T, Tashiro J,
Hirade Y, Kitae K and Tsujikawa K: Discovery of two novel ALKBH5
selective inhibitors that exhibit uncompetitive or competitive type
and suppress the growth activity of glioblastoma multiforme. Chem
Biol Drug Des. 100:1–12. 2022.
|
|
142
|
Selberg S, Seli N, Kankuri E and Karelson
M: Rational design of novel anticancer small-molecule RNA m6A
demethylase ALKBH5 inhibitors. ACS Omega. 6:13310–13320. 2021.
|
|
143
|
Mahapatra L, Andruska N, Mao C, Le J and
Shapiro DJ: A novel IMP1 inhibitor, BTYNB, targets c-Myc and
inhibits melanoma and ovarian cancer cell proliferation. Transl
Oncol. 10:818–827. 2017.
|
|
144
|
Müller S, Bley N, Busch B, Glaß M, Lederer
M, Misiak C, Fuchs T, Wedler A, Haase J, Bertoldo JB, et al: The
oncofetal RNA-binding protein IGF2BP1 is a druggable,
post-transcriptional super-enhancer of E2F-driven gene expression
in cancer. Nucleic Acids Res. 48:8576–8590. 2020.
|
|
145
|
Weng H, Huang F, Yu Z, Chen Z, Prince E,
Kang Y, Zhou K, Li W, Hu J, Fu C, et al: The m6A reader
IGF2BP2 regulates glutamine metabolism and represents a therapeutic
target in acute myeloid leukemia. Cancer Cell. 40:1566–1582.e10.
2022.
|
